Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

457361

registered interest
date	03/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 4 February (HL5344), 11 February (HL5970), and 3 March (HL6245), what are the minimum number of cancer reports that are expected for delivery back to patients by the end of (1) March, (2) June, and (3) September.
tabling member printed	Lord Freyberg
uin	HL6687
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>We are advised by Genomics England that no cancer reports will be returned by the end of March 2016. The priorities for the cancer component of the 100,000 Genomes project are the improvement of the sample processing, sequencing and bioinformatics capabilities across National Health Service Genomic Medicine Centres and Genomics England partnerships. It is unlikely that there will be any clinically actionable reports for cancer in the period to the end of September 2016.</p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:40:25 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2593 label Biography information for Lord Freyberg

457362

registered interest
date	03/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government who is accountable for the project delivery plan for Genomic England’s cancer programme in (1) the Department of Health, and (2) Genomic England.
tabling member printed	Lord Freyberg
uin	HL6688
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>The Director General for Innovation, Growth and Technology in the Department of Health is Senior Responsible Officer for the 100,000 Genomes Project and is responsible for holding delivery partners to account. The Executive Chairman for Genomics England is accountable for delivery of the project.</p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:41:02 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2593 label Biography information for Lord Freyberg

457363

registered interest
date	03/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Genetics: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what timeframe has been agreed for Genomic England to publish a plan with patient volumes that can be shared with Parliament, and what steps they will take to hold the responsible individuals to account if they fail to deliver on any such plan.
tabling member printed	Lord Freyberg
uin	HL6689
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>There are currently no plans to publish future patient volumes. However, the Department holds delivery partners to account for delivery of the project.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:39:47 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2593 label Biography information for Lord Freyberg

457385

registered interest
date	03/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Temporary Employment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what estimate they have made of (1) how many health professionals will return to permanent NHS jobs as a result of price caps on agency staff spending, and (2) how many nurses will leave nursing as a result of those caps.
tabling member printed	Lord Warner
uin	HL6711
answer	answer is ministerial correction date of answer 16/03/2016 answer text <p>No formal assessment has been made by the Department to estimate the specific numbers of health professionals that will return to permanent National Health Service jobs as a result of the introduction of price caps on agency staff spending, or on the number of nurses that may leave nursing as a result.</p><p> </p><p>Trust boards have primary responsibility for monitoring the local impact of the price caps and ensuring patient safety.</p> answering member printed Lord Prior of Brampton question first answered 16/03/2016 16:52:38 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1732 label Biography information for Lord Warner

457386

registered interest
date	03/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Temporary Employment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether NHS trusts can breach price caps on agency spending if they consider that it is essential to do so in order to ensure patient safety.
tabling member printed	Lord Warner
uin	HL6712
answer	answer is ministerial correction date of answer 16/03/2016 answer text <p>NHS trusts are able to override the price caps on agency spending if it is considered essential to do so to ensure the safety of patients.</p><p> </p><p>The circumstances in which trusts can override the caps is set out in the attached guidance: ‘Price Caps for Agency Staff: Rules’.</p> answering member printed Lord Prior of Brampton question first answered 16/03/2016 17:00:31 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name price cap rules.pdf title Price Cap Rules
tabling member	1732 label Biography information for Lord Warner

456831

registered interest
date	02/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prisoners: Learning Disability
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many individual prisoner screening assessments for learning disabilities were undertaken in each prison in England in each of the last five years.
tabling member printed	Lord Bradley
uin	HL6645
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England is currently auditing prison screening for learning disabilities, but this information is not collected centrally at present.</p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:13:33 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	452 label Biography information for Lord Bradley

456335

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what criteria NHS England and NICE will apply when deciding on the commercial agreement to be put in place to provide treatment to patients under the conditional approval route in the new Cancer Drugs Fund.
tabling member printed	Lord Clement-Jones
uin	HL6570
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England has advised that it intends to publish new detailed standard operating procedures for the Cancer Drugs Fund (CDF) by June 2016. These will include any further general details concerning the nature of managed access agreements associated with a drug’s entry into the Fund.</p><p>The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for National Health Service patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of the National Institute for Health and Care Excellence, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL6571 question first answered 14/03/2016 15:27:18 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3396 label Biography information for Lord Clement-Jones

456336

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what types of commercial agreements NHS England and NICE will be required to consider as part of the conditional approval route in the new Cancer Drugs Fund.
tabling member printed	Lord Clement-Jones
uin	HL6571
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England has advised that it intends to publish new detailed standard operating procedures for the Cancer Drugs Fund (CDF) by June 2016. These will include any further general details concerning the nature of managed access agreements associated with a drug’s entry into the Fund.</p><p>The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for National Health Service patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of the National Institute for Health and Care Excellence, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL6570 question first answered 14/03/2016 15:27:18 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3396 label Biography information for Lord Clement-Jones

456337

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of NHS England’s and NICE’s capabilities in relation to the commercial negotiations between them and pharmaceutical manufacturers in respect of the conditional approval route under the new Cancer Drugs Fund.
tabling member printed	Lord Clement-Jones
uin	HL6572
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England’s Board agreed, on 25 February 2016, a way forward which will see the proposed new arrangements for the Cancer Drugs Fund (CDF) going live on 1 July 2016</p><p><br> We expect NHS England and the National Institute for Health and Care Excellence (NICE) to work together to ensure that both organisations have the necessary capability and capacity to implement these proposals, including the introduction of a conditional approval route.</p><p> </p><p>The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for NHS patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of NICE, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.</p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 14/03/2016 15:16:31 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	3396 label Biography information for Lord Clement-Jones

456349

registered interest
date	01/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what work NHS England and Monitor are undertaking to develop new payment and incentives mechanisms that drive integrated care for diabetes across primary and secondary care settings; and what is the time frame for any new proposals to be published.
tabling member printed	Lord Harrison
uin	HL6583
answer	answer is ministerial correction date of answer 14/03/2016 answer text <p>NHS England and Monitor are working closely together to ensure that the payment system supports service developments in the vanguard sites (including those where integrated diabetes care is a focus) as well as monitoring local innovative approaches to supporting integrated care taken by some clinical commissioning groups (CCGs). This is to ensure that the payment system keeps abreast with the development of future service models and is not a barrier to the development of new models of care.</p><p> </p><p>During 2016/17, NHS England will look at the current incentives and funding arrangements for diabetes to see how greater alignment could be achieved between the financial incentives for primary and secondary care.</p><p> </p><p>Information on how much money the National Health Service invested in structured education for diabetes patients is not collected centrally.</p><p> </p><p>Under the Health and Social Care Act (2012), NHS England has a statutory duty to conduct an annual assessment of every CCG. Since April 2013, CCGs have been assessed twice, for the period 2013/14 and for 2014/15.</p><p> </p><p>For 2016/17, NHS England will introduce a new CCG Improvement and Assessment Framework (CCG IAF). This new framework will align with NHS England’s mandate and planning process, with the aim of driving improvements in a number of key areas including the management and care of people with diabetes.</p><p> </p><p> </p><p>NHS England has been working with Diabetes UK on including diabetes indicators in the CCG IAF. The proposed diabetes indicators are:</p><p> </p><p>- the percentage of diabetes patients that have achieved all three of the National Institute for Heath and Care Excellence recommended treatment targets; and</p><p>- newly diagnosed diabetes patients referred to, or attending, a structured education course.</p><p> </p><p>Under the proposals, diabetes will also be one of the six clinical priority areas in the CCG IAF that will be overseen by an independent group.</p><p> </p><p>The CCG IAF proposals are subject to the outcome of an engagement process which closed for comments on February 26 2016. More information can be found at:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/ccg-improvmnt/" target="_blank">https://www.england.nhs.uk/commissioning/ccg-improvmnt/</a></p> answering member printed Lord Prior of Brampton grouped question UIN HL6585 HL6586 question first answered 14/03/2016 15:15:42 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2488 label Biography information for Lord Harrison